An end-to-end automated platform process for high-throughput engineering of next-generation multi-specific antibody therapeutics

• Main Authors: Norbert Furtmann (Author), Marion Schneider (Author), Nadja Spindler (Author), Bjoern Steinmann (Author), Ziyu Li (Author), Ingo Focken (Author), Joachim Meyer (Author), Dilyana Dimova (Author), Katja Kroll (Author), Wulf Dirk Leuschner (Author), Audrey Debeaumont (Author), Magali Mathieu (Author), Christian Lange (Author), Werner Dittrich (Author), Jochen Kruip (Author), Thorsten Schmidt (Author), Joerg Birkenfeld (Author)
• Format: Book
• Published: Taylor & Francis Group, 2021-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Next-generation multi-specific antibody therapeutics (MSATs) are engineered to combine several functional activities into one molecule to provide higher efficacy compared to conventional, mono-specific antibody therapeutics. However, highly engineered MSATs frequently display poor yields and less fa...